Generics Makers Weigh in on ANDA Filing Draft Guidance

Generic Line
To improve ANDA submissions, the FDA should spend more time with generics companies before they file an application, as is done with brand manufacturers in the run-up to an NDA, the Generic Pharmaceutical Association says.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00